For laboratory research use only. Not for human consumption.

Timeline8 milestones

Selank Research Timeline

Selank is a synthetic heptapeptide derived from tuftsin, a naturally occurring immunomodulatory peptide. Developed alongside Semax at the Institute of Molecular Genetics in Russia, Selank has been studied for its effects on anxiety-related behaviors, GABAergic neurotransmission, and immune system regulation. Its dual neuro-immune research profile distinguishes it from most other neuropeptide analogs.

1980s

Design and synthesis from tuftsin

Researchers designed Selank by extending the naturally occurring tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a stabilizing Pro-Gly-Pro sequence. This modification was intended to increase enzymatic stability while preserving the immunomodulatory properties of the parent compound.

1994–1996

Anxiolytic properties studied

Early behavioral studies in rodent models documented that Selank reduced anxiety-like behaviors in elevated plus maze and open field tests. Researchers noted the absence of sedative effects commonly associated with benzodiazepine-class anxiolytics.

2003

Conditioned avoidance reflex research

Kozlovskii and Danchev published findings on Selank's optimizing effects on conditioned active avoidance reflexes in rats. This study characterized the compound's influence on learning and adaptive behavior under stress conditions.

Neurosci Behav Physiol

2006–2008

GABAergic mechanism research

Research teams documented that Selank affects the expression of genes involved in GABAergic neurotransmission, including enzymes responsible for GABA synthesis and metabolism. These findings provided a molecular basis for the observed anxiolytic-like effects in behavioral models.

2009–2011

Immunomodulatory properties characterized

Studies explored Selank's effects on cytokine expression, including IL-6 modulation, and documented changes in immune cell function. This research connected the compound's tuftsin-derived structure to measurable immunological effects.

2014

Gene expression profiling in brain tissue

Transcriptomic studies revealed that Selank modulates expression of genes associated with serotonin transport, GABA receptor signaling, and inflammatory pathways in the hippocampus and frontal cortex of rats.

2016–2018

Enkephalin degradation research

Researchers documented that Selank inhibits enzymes involved in enkephalin degradation, suggesting an additional mechanism through which it may influence stress and mood-related pathways. This finding added a novel dimension to the compound's pharmacological profile.

2020–2023

Integrated neuro-immune studies

Later research examined the intersection of Selank's neurotropic and immunomodulatory effects, exploring how the compound influences both central nervous system function and peripheral immune responses simultaneously.

Why This Research Matters

Selank's research trajectory highlights an unusual compound profile that bridges neuroscience and immunology. Its derivation from an immune peptide (tuftsin), combined with documented effects on GABAergic and enkephalinergic systems, positions it at a unique research intersection. The progression from behavioral observation to gene expression analysis demonstrates how modern molecular tools can deepen understanding of peptide mechanisms identified through classical pharmacology.

Research Use Compliance

All information presented in this article references published research literature and is intended for educational purposes only. Research peptides are sold strictly for laboratory research use and are not approved for human consumption or medical treatment.